Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

NCT01591161 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

369

Enrollment

INDUSTRY

Sponsor class

Conditions

Cataract
Inflammation
Surgery

Interventions

DRUG: Mapracorat
DRUG: Placebo

Sponsor

Bausch & Lomb Incorporated